Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

These weight loss medications, administered via injections, work by mimicking a hormone called GLP-1, which helps regulate appetite and blood sugar levels.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...